Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CNR1 | P21554 | 3/20 | 0.47 |
| ▸ | CNR2 | P34972 | 3/20 | 0.47 |
| ▸ | JAK2 | O60674 | 1/20 | 0.46 |
| ▸ | CDK8 | P49336 | 1/20 | 0.46 |
| ▸ | MAPK14 | Q16539 | 10/20 | 0.46 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.45 |
| ▸ | GRN | P28799 | 2/20 | 0.44 |
| ▸ | SORT1 | Q99523 | 2/20 | 0.44 |
| ▸ | HPGD | P15428 | 1/20 | 0.44 |
| ▸ | MAPK13 | O15264 | 4/20 | 0.44 |
| ▸ | MAPK12 | P53778 | 4/20 | 0.44 |
| ▸ | MAPK11 | Q15759 | 4/20 | 0.44 |
| ▸ | LMNA | P02545 | 1/20 | 0.43 |
| ▸ | MAPT | P10636 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16739349 | 0.85 | CNR1 (0.62) | CNR1CNR2JAK2MAPK14 | |
| SCHEMBL28751503 | 0.81 | AURKA (0.43) | LMNA | |
| SCHEMBL1012925 | 0.81 | MAPK14 (0.48) | JAK2MAPK14NPSR1GRNSORT1 | |
| SCHEMBL12074507 | 0.81 | CDK8 (0.41) | CNR1CNR2JAK2CDK8MAPK14 | |
| SCHEMBL4603361 | 0.80 | MAPK14 (0.44) | CNR1CNR2JAK2MAPK14NPSR1 | |
| SCHEMBL1699062 | 0.80 | MAPK14 (0.61) | CNR2MAPK14GRNSORT1MAPK13 | |
| SCHEMBL9988597 | 0.79 | ALDH1A1 (0.47) | JAK2NPSR1HPGDLMNAMAPT | |
| SCHEMBL284059 | 0.77 | MAPK14 (0.45) | CNR1CNR2JAK2MAPK14NPSR1 | |
| SCHEMBL2311794 | 0.77 | GRN (0.66) | CNR1CNR2NPSR1GRNSORT1 | |
| SCHEMBL4963431 | 0.77 | MAPK14 (0.43) | CNR1CNR2JAK2CDK8MAPK14 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9771353-B2 | Kinase inhibitors based upon N-alkyl pyrazoles | TOPIVERT PHARMA LIMITED (GB) | 2017-09-26 | — | — | US | disclosed |
| EP-2981534-B1 | KINASE INHIBITORS BASED UPON N-ALKYL PYRAZOLES | TOPIVERT PHARMA LTD (GB) | 2017-07-19 | — | — | EP | disclosed |
| US-20160039797-A1 | KINASE INHIBITORS BASED UPON N-ALKYL PYRAZOLES | OXULAR ACQUISITIONS LIMITED (GB) | 2016-02-11 | — | — | US | disclosed |
| EP-2981534-A1 | KINASE INHIBITORS BASED UPON N-ALKYL PYRAZOLES | Topivert Pharma Limited (GB) | 2016-02-10 | — | — | EP | disclosed |
| WO-2014162121-A1 | KINASE INHIBITORS BASED UPON N-ALKYL PYRAZOLES | TOPIVERT PHARMA LIMITED (GB) | 2014-10-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160039797-A1 | KINASE INHIBITORS BASED UPON N-ALKYL PYRAZOLES | SYK, LCK, BTK | CNR1 2923/4885CNR2 2779/4885JAK2 162/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.